Book chapters will be unavailable on Saturday 24th August between 8am-12pm BST. This is for essential maintenance which will provide improved performance going forwards. Please accept our apologies for any inconvenience caused.
To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
A biomarker is an objectively measured and evaluated characteristic which is an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention (Group,2001). Physicians in clinical practice routinely use biomarkers to diagnose and assess disease severity, assist in disease prognosis, and evaluate treatment efficacy. Generally, injury and/or cell death results in increased concentrations of a given biomarker, either due to the release of that biomarker from the injured cell (e.g. creatine phosphokinase (CPK) in patients with myocardial infarction) or the lack of excretion of a normally excreted chemical which results in its accumulation (e.g. blood urea nitrogen in patients with renal failure). In some cases, however, a decrease in biomarker concentrations indicates pathology (e.g. haptoglobin in patients with hemolytic anemia).
Development of a clinically acceptable “brain” biomarker has proven much more difficult than the development of biomarkers for other organs. The difficulty is likely due to a combination of anatomic, physiologic, and technical issues. The complexity of the brain and the concomitant complexity of its response to injury have been barriers to development of sensitive and specific brain biomarkers. The presence of the blood–brain barrier which limits the amount and size of the biomarkers that can cross into the serum has also been an important issue. Until recently, technical difficulties had hindered the ability to identify novel candidate biomarkers using proteomics and, as a result, the number of potential biomarkers has been limited.
Email your librarian or administrator to recommend adding this to your organisation's collection.